Archive for October, 2011

Treprostinil Alleviates Pulmonary Hypertension Symptoms

Tuesday, October 18th, 2011

treprostinil sodiumPatients with pulmonary hypertension can look at Treprostinil and breathe a sigh of relief. For years, this type of hypertension has been managed by a limited choice of treatment options such as oxygen, vasodilators and prostaglandins. These two treatment options are used to “open up” the arteries which results in reduced pressure in the blood vessels. Treprostinil belongs to the prostaglandin class of drugs, and acts by inhibiting prostaglandin production in the body. Since the body reacts to inflammation by releasing prostaglandins to signal distress, the drug treprostinil inhibits their release in the affected blood vessels of patients with pulmonary hypertension. The disease mechanism is not fully understood; however, several factors are cited in the eventual swelling of the arteries which limit the oxygen supply to certain vital organs that ultimately lead to increased blood pressure in these vessels.

Illustration courtesy of www.remodulin.com

Scientists have not fully understood the mechanism behind pulmonary hypertension, therefore limiting the therapeutic approaches to pharmacologic and non-pharmacologic treatments. The disease is incurable; however, scientists at UCLA have instead focused their studies on improving the quality of life of its long time sufferers. The multicenter, randomized trial tested 470 patients with treprostinil infusion and compared its results with placebo. The patients’ responses to the drug were measured by their ability to perform basic physical activities such as walking. The results showed significant improvement in alleviation of symptoms (reduced incidence of shortness of breath) while performing the physical activities. Also, when hemodynamic parameters were assessed, the patients on treprostinil showed less vascular resistance, an important indicator of decreased arterial inflammation. The study has certainly paved the way for improving the day to day functionality of patients living with this disease.

LGM Pharma works closely with educational institutions that are actively developing and improving existing treatment options in the field of medical research. With the company’s promise of timely delivery and adherence to international regulatory standards, institutions can focus entirely on their field, knowing that their supplier of research molecules like Treprostinil Sodium CAS# 289480-64-4 are reliable, and reputable in the world of pharmaceutical supply chain.

Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk.

Ivabradine Cuts Heart Failure Mortality Rates

Tuesday, October 18th, 2011
heart rate in cardiovascular pathophysiology

Illustration courtesy of http://www.shift-study.com

A study presented at the European Society of Cardiology (ESC) Congress 2010 gives promising results to patients suffering from heart failure with tachycardia (increased heart rate). The study, called Systolic Heart Failure Treatment with If Inhibitor Ivabradine Trial (SHIFT), provided scientists with a strong case for ivabradine’s usefulness as an adjunct agent in the treatment of chronic heart failure (CHF). The drug acts on the SA node of the heart and slows down its rapid beating, one of the discussants of the study, Dr. Anand of the University of Minnesota said. Another important implication of the results points out to the role of increased heart rate as a mediator in the disease progression of CHF.

Heart failure, characterized by the inability of the heart to cope with the blood flow needs of the body, can result from numerous abnormal conditions such as coronary artery disease, congenital heart defects and drug abuse among others. It is a debilitating and consequently deadly condition if left mismanaged in the long run. Current treatment guidelines that include the use of beta blockers have their pitfalls when used in patients who are unable to tolerate higher doses of this class of drugs. The results of the SHIFT study promises to pick up on the shortcomings of beta blockers in this area by improving the quality of life of its sufferers.

Dr. Clyde Yancy of Baylor University Medical Center, Texas expressed his lukewarm response to the results, saying that genetic differences must be taken into account before using ivabradine that is solely based on the SHIFT study. Since participants of the study were from outside US and Western Europe, he says that predicting clinical outcomes on a broader patient population is difficult which is why he encourages further studies on the drug.

ivabradine hydrochlorideLGM Pharma currently works with various educational institutions and medical centers who are actively engaged in further R&D of the drug, ivabradine. Ivabradine Hydrochloride CAS# 148849-67-6 is supplied by LGM Pharma to its clients. The company’s strict adherence to international and local regulatory standards has made it the supplier of choice for research molecules by global pharmaceutical firms.

Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk.

Gliptins Give Researchers a Pleasant Cardiovascular Surprise

Wednesday, October 12th, 2011

gliptinsDDP-4 inhibitors, commonly known as Gliptins, are a relatively new group of drugs. They are drugs normally used for diabetes control, however, this year it was discovered that they may play a greater heart-protective role in patients with existing cardiovascular comorbidities.

According to the report published last month in Medpage Today, researchers found that patients being treated with the DDP-4 inhibitor class of drugs had a 30% cardiovascular event risk reduction. Dr. Manucci of the Diabetes Agency at Careggi Teaching Hospital in Florence, Italy reports that these findings were evident in the meta-analyses involving 53 clinical trials and 33,000 patients.

The discovery was met with startled albeit pleasant reactions by researchers since they were initially seeking evidence for the antidiabetic drugs’ associated cardiovascular risks rather than its cardioprotective effects. The initial meta-analyses was spurred on by the FDA’s stringent requirements on drug companies to limit all diabetic drugs’ risk of cardiovascular events to less than 30% in comparison with placebo.

The results of the meta-analyses do not explain the mechanism by which the gliptins protect the heart, however, the news of the drugs’ cardioprotective effects are encouraging enough to those in the health and pharmaceutical industry. Doctors now have another solid reason to prescribe these drugs in lieu of the other hypoglycemic agents which come with unwanted cardiovascular risks. Scientists, drug companies and drug suppliers are encouraged by these results, and now have a renewed purpose to purchase these drugs from LGM Pharma, as well as research institutions looking to investigate them for possible cardiovascular protective indications.

LGM Pharma currently has the following gliptin API’s readily available for prompt shipment:

Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk.

Iloprost favors the quitters in the battle against lung cancer

Wednesday, October 5th, 2011

Tobacco SmokingIn a world where about a third of the adult male in the global population smokes, it’s tough not to take notice of its negative impact on the society as a whole. According to the WHO, if the smoking trends do not ease up, one in every 6 adults will die of smoking-related illness (e.g. emphysema and lung cancer) by 2030. Currently, smoking-related diseases kill 1 in 10 adults worldwide.

Chilling reports aside, the threat of diseases caused by smoking has not gone unnoticed by the public. In the recent years, pharmaceutical companies  have helped smokers quit the habit by coming up with smoking cessation aids; from nicotine patches to nicotine gums. However, some smokers have smoked too much for far too long that the damage done to their respiratory systems are already irreversible.

At the American Association for Cancer Research (AACR) Annual Meeting this year, iloprost took to the stage with positive results of its Phase II trial testing its effect on cancer cells in the lungs of former smokers. The study, headed by Dr. Robert L. Keith of the University of Colorado, tested the antihypertensive drug, iloprost 150 mcg, on former and current smokers, who have had at least a 20 pack year (1 pack/20 cigarettes per day for 20 years) in their lifetime.  After taking biopsies of former smokers’ lungs, the study reported significant reductions in lesions. However, the biopsies of current smokers showed no changes.

Lung CancerIloprost CAS# 78919-13-8 is a prostaglandin analog of the naturally occurring PG12, a prostaglandin with antimetastatic properties.  In patients with lung cancer, PG12 levels are reduced in the lungs. However, in healthy patients, PG12 levels are increased.

The study is an entirely new treatment concept in the battle against lung cancer. However, the drug still has a long way to go before it can even make it to the phase 3 of clinical testing. This is why LGM Pharma provides continuous supply support to institutions currently involved in its research and development. The company understands the critical role of a reliable supply chain for these institutions, which is why they never compromise on the timely delivery of their products.

Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk.